Johnson & Johnson
AbbVie — based in North Chicago — said late Wednesday that it will pay $261.25 a share for Pharmacyclics, which makes Imbruvica, a drug approved to treat three different types of blood cancers. That represents a premium of about 21 percent to the closing price of Pharmacyclics shares on Tuesday.
Johnson & Johnson has agreed to pay more than $2 billion to settle some serious criminal and civil charges with the federal government. CBS 2’s Jim Williams reports.
The makers of Tylenol are facing a new lawsuit filed by an Illinois family on an old recall.
New revelations have surfaced about the origin of the infamous Tylenol poisonings nearly three decades ago.
There’s good news for millions of people with mild or moderate heart failure.